Trial · NCT01589302
Results by group62
Each measurement the trial posted, group by group, in the words and numbers it posted.
21 to 40 of 62
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Patients With Adverse Events, Graded According to the NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 | Treatment (Ibrutinib) | Gastric Hemorrhage | 1 | patients | |
| Number of Patients With Adverse Events, Graded According to the NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 | Treatment (Ibrutinib) | Gastrointestinal Disorders-other | 1 | patients | |
| Number of Patients With Adverse Events, Graded According to the NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 | Treatment (Ibrutinib) | Mucositis Oral | 1 | patients | |
| Number of Patients With Adverse Events, Graded According to the NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 | Treatment (Ibrutinib) | Nausea | 2 | patients | |
| Number of Patients With Adverse Events, Graded According to the NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 | Treatment (Ibrutinib) | Death | 1 | patients | |
| Number of Patients With Adverse Events, Graded According to the NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 | Treatment (Ibrutinib) | Edema Limb | 1 | patients | |
| Number of Patients With Adverse Events, Graded According to the NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 | Treatment (Ibrutinib) | Fatigue | 1 | patients | |
| Number of Patients With Adverse Events, Graded According to the NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 | Treatment (Ibrutinib) | General Disorders and Admin Site Conditions | 2 | patients | |
| Number of Patients With Adverse Events, Graded According to the NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 | Treatment (Ibrutinib) | Cholecystitis | 1 | patients | |
| Number of Patients With Adverse Events, Graded According to the NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 | Treatment (Ibrutinib) | Bronchial Infection | 1 | patients | |
| Number of Patients With Adverse Events, Graded According to the NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 | Treatment (Ibrutinib) | Infections and Infestations-other | 4 | patients | |
| Number of Patients With Adverse Events, Graded According to the NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 | Treatment (Ibrutinib) | Lung Infection | 10 | patients | |
| Number of Patients With Adverse Events, Graded According to the NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 | Treatment (Ibrutinib) | Otitis Media | 1 | patients | |
| Number of Patients With Adverse Events, Graded According to the NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 | Treatment (Ibrutinib) | Sepsis | 2 | patients | |
| Number of Patients With Adverse Events, Graded According to the NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 | Treatment (Ibrutinib) | Skin Infection | 2 | patients | |
| Number of Patients With Adverse Events, Graded According to the NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 | Treatment (Ibrutinib) | Urinary Tract Infection | 1 | patients | |
| Number of Patients With Adverse Events, Graded According to the NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 | Treatment (Ibrutinib) | Alanine Aminotransferase Increased | 1 | patients | |
| Number of Patients With Adverse Events, Graded According to the NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 | Treatment (Ibrutinib) | Blood Bilirubin Increased | 1 | patients | |
| Number of Patients With Adverse Events, Graded According to the NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 | Treatment (Ibrutinib) | Lymphocyte Count Decreased | 14 | patients | |
| Number of Patients With Adverse Events, Graded According to the NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 | Treatment (Ibrutinib) | Lymphocyte Count Increased | 54 | patients |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01589302/results?page=2